Skip to contentS
Starling Oncology, Inc.
S
STLNStarling Oncology, Inc. Q2 2024 · 10-Q
Revenue$98.58M$98.58M+22.9% vs Q2 2023 Net Income-$15.48M-$15.48MN/M vs Q2 2023 EPS Diluted-$0.17-$0.17N/M vs Q2 2023 Operating Income-$16,364,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$17,486,000N/M Margins · derivedOperating margin-16.6%+2.0 pt vs Q2 2023
Net margin-15.7%+5.4 pt vs Q2 2023
ended Jun 30, 2024 · filed Aug 13, 2024 · 44 d after period end